Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

A Novel PROTAC G9a/GLP Degrader that Inhibits, Similar to G9a siRNA, the Migration of MCF-7 Breast-Cancer Cells without Affecting Proliferation.

Journal of medicinal chemistry·2025
Same author

Investigating the nutritional status characteristics of terminal cancer patients by the type of cancer.

Fujita medical journal·2025
Same author

Cell-free and concentrated pleural effusion reinfusion therapy with aggressive nutritional support improved refractory pleural effusion in a patient with malnutrition after distal gastrectomy for gastric cancer.

Fujita medical journal·2025
Same author

Isolated splenic tuberculosis in a patient with rheumatoid arthritis.

IDCases·2025
Same author

FAXC depletion contributes to tumor progression via the c-MET pathway in renal cell carcinoma.

Biochemical and biophysical research communications·2025
Same author

Transcutaneous CO<sub>2</sub> and O<sub>2</sub> monitoring during walking with a high-flow nasal cannula in patients with chronic obstructive pulmonary disease.

Respiratory investigation·2025

相关实验视频

Updated: Sep 9, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

通过影响血管内皮生长因子信号传递,对抗氨酸激酶抑制剂耐药的细胞癌细胞在体外和体内产生抗瘤作用.

Kento Morozumi1, Yoshihide Kawasaki2, Izumi Sakamoto2

  • 1Department of Urology, Tohoku Medical and Pharmaceutical University, Miyagi, Japan; Department of Urology, Tohoku University Graduate School of Medicine, Miyagi, Japan.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|August 30, 2025
PubMed
概括
此摘要是机器生成的。

通过使用谷氨酸酶抑制剂 (GLSi) 控制谷氨酸代谢,可以在晚期细胞癌中克服氨酸激酶抑制剂 (TKI) 耐药性. 这种方法使癌细胞对TKI重新敏感,从而有可能改善患者的预后.

关键词:
时间TKI 的阻力在VEGFR葡萄糖胺酶胺的代谢细胞癌

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

相关实验视频

Last Updated: Sep 9, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

科学领域:

  • 癌症学
  • 分子生物学
  • 癌症新陈代谢

背景情况:

  • 氨酸激酶抑制剂 (TKIs) 在晚期细胞癌 (RCC) 治疗中至关重要.
  • 药物耐药性限制了TKIs在RCC患者的长期疗效.
  • 之前的研究发现了与苏尼替尼抗药性相关的代谢途径.

研究的目的:

  • 调查是否针对谷氨酸代谢途径可以克服癌中的TKI耐药性.
  • 在耐性癌模型中评估与谷氨酸酶抑制剂 (GLSi) 结合的抗瘤效应.

主要方法:

  • 已建立多个对苏尼替尼和卡博赞提尼抗性癌细胞系.
  • 在耐药细胞中分析了胺代谢途径的改变.
  • 使用一种谷氨酸酶抑制剂 (GLSi) 来抑制谷氨酸代谢.
  • 评估了GLSi与TKI结合的体外和体内的抗瘤作用.
  • 研究GLSi抗瘤活性的潜在分子机制.

主要成果:

  • 癌细胞的TKI耐药性与增加的谷氨酸代谢相关.
  • 在所有耐药细胞系中,GLSi显著抑制了增殖,侵入和迁移.
  • 结合GLSi和TKI治疗在耐药瘤中显示出强烈的抗血管效应.
  • 由GLSi诱导的谷氨酸降低激活了PETN,导致VEGFR信号传递和抗瘤作用的降低.

结论:

  • 在晚期细胞癌中,胺代谢对TKI耐药性起着至关重要的作用.
  • 通过GLSi抑制谷氨酸代谢可以使耐受性癌细胞对TKIs重新敏感.
  • 针对谷氨酸代谢提供了一种有前途的策略,以提高TKI的疗效,并改善晚期RCC患者的治疗结果.